Keiretsu Capital Joins National Venture Capital Association

Keiretsu Capital is proud to announce its membership with the National Venture Capital Association (NVCA). The leading trade organization for venture capital firms, NVCA membership provides a myriad of benefits to the Keiretsu Capital team and investors. 


About the NVCA

As the voice of the U.S. venture capital community, the National Venture Capital Association (NVCA) empowers its members and the entrepreneurs they fund by advocating for policies that encourage innovation and reward long-term investment.  As the venture community’s flagship trade association, the NVCA serves as the definitive resource for venture capital data and unites its member firms through a full range of professional services.

Keiretsu Launches AngelList Syndicate Network

This AngelList syndicate allows our members and other interested investors to co-invest pari passu into companies that have already gone through exhaustive due diligence and have been backed by the angels. By backing this syndicate you get to see all the companies still raising funding with no obligation to invest in them. 

This is an ideal way to invest if you don't have time to be an active Keiretsu angel investor or do not want to invest at the minimum level for direct investment.

See our syndicated deals with no obligation to invest:

HALO Report 2016: Keiretsu Forum Ranked #1 Multi-Chapter Angel Group

Keiretsu Forum is proud to be ranked as the #1 most active angel investment group in 2016 (multi-chapter angel groups). 

About the HALO Report

The HALO Report provides analysis and trends on US angel and angel group activity. Angels and angel groups invest alone, together, and with many other types of investors. Unless otherwise noted the HALO Report data includes all rounds that have at least one angel group participating and may include other types of investors in those rounds. Deals where individual angels and angel groups represented only a small percentage of the total funding were removed from the calculations on valuation and round sizes. 

"Build Your Fortune in the Fifth Era" - New Release from Keiretsu's Matthew Le Merle & Alison Davis

April 14, 2017
Jennifer Bulotti


Authors Share Industry Secrets on How to Participate in New Era

SAN FRANCISCO, CA--(April 14, 2017) – In their new book, Build Your Fortune in the Fifth Era, Silicon Valley insiders Matthew C. Le Merle and Alison Davis reveal invaluable insights on how to participate and prosper in the Fifth Era – this coming age of unprecedented innovation and change.

“The Internet didn’t even exist 30 years ago, and now billions of people are connected to the web every day, and remarkable new technologies have been invented that will dramatically change the way humans exist on our planet,” said Alison Davis, co-founder of Fifth Era (, a San Francisco-based firm focused on innovation, investing and advising. “This emerging playing field is not well understood and so we have attempted to demystify it for everyone.”

Today’s most valuable companies are Fifth Era companies—built in the spirit of entrepreneurialism and technological innovation. Likewise, many of the richest people in the world today are first generation technology entrepreneurs or investors in innovation. This book identifies ways to build a fortune during this time of extraordinary wealth creation opportunities.

“Despite the dramatic pace of change and the enormous wealth being created, most people are missing out,” said Matthew C. Le Merle, co-founder of Fifth Era and managing partner of Keiretsu Capital, the most active venture investor in the US. “The tens of millions of households in the US and around the world who could participate in early stage companies - which provide the highest returns to venture and angel investors - hardly ever do.”

The book, has earned the accolades of Silicon Valley entrepreneurs and investment icons:

“The authors have been focused on innovation for most of their working careers. This book shares the lessons they have learned as investors, advisors and board directors.”
Tony Hsieh, NY Times Bestselling Author, CEO

"People are constantly asking me questions about angel investing and venture capital. Read this book if you want to understand the capital that fuels the entrepreneurs and technology innovation changing the world."
Keith Rabois, General Partner, Khosla Ventures

“No one can read this book and not be left struck by the uniqueness of our time, the potential for wealth creation, and the importance of embracing change.”
Eric Stang, Chairman/CEO, Ooma

“Build Your Fortune in the Fifth Era is a timely and important read. Alison and Matthew share their deep and broad experience to encourage broader participation in the investment opportunity that is one of the most unique, and potentially rewarding, of our lifetime."
Tracey Brophy Warson, North America Private Banking Head

The book will be officially launched industry-wide at the Bay Area Angel Capital Expo, a premier gathering of the angel investment community, bringing together investors and entrepreneurs. Attendees include more than 500 investors, venture capitalists, and CEOs. Book co-authors Le Merle and Davis are among the keynote speakers.

Alison Davis is co-founder of Fifth Era ( She is a global strategist, finance professional, public company board director and active investor in growth companies. She was CFO at BGI (Blackrock), GP at Belvedere Capital, and a strategy consultant at McKinsey and A.T. Kearney. Alison has degrees from Cambridge (MA/BA) and Stanford (MBA). She was born in Sheffield, UK and now lives in the San Francisco Bay Area with her husband, Matthew C. Le Merle, and their five children.

Matthew Le Merle is co-founder of Fifth Era ( and managing partner of Keiretsu Capital, the world’s largest angel network and most active US venture investor. Matthew is a sought-after speaker and innovation consultant having worked at McKinsey, A.T. Kearney, Monitor, Booz and Gap. Matthew has degrees from Christ Church, Oxford (MA/BA) and Stanford (MBA). He was born in London, UK and now lives in the San Francisco Bay Area with his wife, Alison Davis, and their five children.

Fifth Era invests in and incubates early stage technology-enabled companies. The managing team also advises companies and conducts development initiatives to support innovation and growth strategies. For more information, visit

Book available on Amazon April 20, 2017
Find us on Facebook, Twitter and LinkedIn

Blaze Bioscience Announces Tumor Paint BLZ-100 Publication in International Journal of Toxicology

Blaze Bioscience Announces Tumor Paint BLZ-100 Publication in International Journal of Toxicology

Safety pharmacology, PK and toxicology studies supported first-in-human clinical trials

SEATTLE, WA – March 28, 2017 – Blaze Bioscience, Inc., the Tumor Paint Company®, a biotechnology company dedicated to improving the lives of cancer patients, today announced the publication of a peerreviewed manuscript in International Journal of Toxicology describing the nonclinical safety and pharmacokinetic (PK) profile of Tumor Paint BLZ-100 in animal models. The publication entitled “Nonclinical Profile of BLZ-100, a Tumor Targeting Fluorescent Imaging Agent” by Parrish-Novak et al is available online and will be available in print in an upcoming issue of International Journal of Toxicology.

The publication outlines a series of studies to evaluate the pharmacokinetic and toxicology profile of BLZ- 100 in animals after a single dose. The publication also discusses safety observations from a separate imaging pharmacology study conducted in mixed-breed dogs with naturally occurring tumors, a study fully funded by the National Cancer Institute (NCI) through a Phase 1 Small Business Innovation Research (SBIR) contract1 .

The combined studies established the nonclinical profile for BLZ-100, supporting the first-in-human clinical trials. Tumor Paint BLZ-100 is currently being tested in ongoing Phase I clinical studies in pediatric brain cancer and breast cancer, and has completed Phase I testing in skin cancer and adult brain cancer.

“These nonclinical studies were an integral part to initiating the clinical program for Tumor Paint BLZ-100,” said Dr. Dennis Miller, Blaze Bioscience SVP of Development. “The definitive toxicology studies in rats and non-human primates demonstrated safety with intravenous doses over 100-fold safety margin for our initial clinical doses.”

About BLZ-100

BLZ-100 is the first product candidate from Blaze’s Tumor Paint platform and consists of an Optide (optimized peptide) and a fluorescent dye, which emits light in the near-infrared range. Tumor Paint products are designed to provide real-time, high-resolution intraoperative visualization of cancer cells, potentially enabling more precise, complete resection of cancer throughout surgery. Preclinical utility of Tumor Paint technology has been demonstrated in a wide range of cancer types. BLZ-100, an investigational agent, is in Phase I clinical studies to evaluate the safety and imaging characteristics of BLZ-100 in solid tumors. BLZ-100 has achieved clinical proof of concept in brain, breast and skin cancers. Additional potential applications of BLZ-100 include prostate, lung, colorectal and other solid tumor cancers. More details about on-going trials are available at or

About Blaze Bioscience

Blaze Bioscience, Inc. is a privately held biotechnology company dedicated to improving the lives of cancer patients. Blaze was founded in 2010 by Dr. Jim Olson, a pediatric neuro-oncologist at the Fred Hutchinson Cancer Research Center and Seattle Children’s Hospital, and Heather Franklin, a former member of the executive management team at ZymoGenetics. Blaze is working to develop Tumor Paint products and Optide-based therapeutics. Surgery is first-line therapy for most solid tumor cancers and Tumor Paint products have the potential to improve cancer surgery by providing real-time, high-resolution visualization of cancer cells throughout surgery. The ability to see cancer cells in real time and high resolution throughout surgery should enable better detection and more complete and precise surgical removal of cancer—while sparing surrounding normal tissue. In addition to the Tumor Paint platform, Blaze is collaborating with the Fred Hutchinson Cancer Research Center to discover and develop products based on knottin peptides as part of the Optides platform. This program extends the expertise gained in developing the Tumor Paint platform to optimized knottin peptides for therapeutic and imaging applications.

1 This project has been funded in whole with Federal funds from National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201200054C.

For additional information, please visit

Investors and Media:

Lauren Nelson Blaze Bioscience, Inc.
(206) 535-8144

Keiretsu Ranked #1 Active VC Investor in Pitchbook 2016 Annual Report

We are proud to share that the Keiretsu Global Network was ranked ten times in the 2016 Annual Report from Pitchbook. The full report is available below for you to read and share.

See a complete list of rankings below – all are Keiretsu Forum unless otherwise indicated, rank on list indicated in parentheses:

  • Most Active VC Investor at Seed/Angel Stage – Keiretsu Forum (1st)
  • Most Active VC Investor – West Coast Deals (1st)
  • Most Active VC Investor – US Deals (2nd)
  • Most Active VC Investor – Deals in the Rest of World (3rd)
  • Most Active VC Investor in Pharma & BioTech (3rd)
  • Most Active VC Investor in Consumer Goods (3rd)
  • Most Active VC Investor in IT Hardware (7th)
  • Most Active VC Investor – Mid-Atlantic Deals (8th)
  • Most Active VC Investor at Seed/Angel Stage – Keiretsu Capital (22nd)
  • Most Active VC Investor at Late Stage (22nd)

Keiretsu Company Savara Exits for $115M

Savara and Mast to Merge to Progress Clinical Pipeline of Inhaled Drugs

    • Savara Pharmaceuticals and Mast Therapeutics agreed a stock-based merger deal that values Mast at $36.5 million and Savara at $115 million. Under terms of the proposed deal, which was announced over the weekend, Savara’s shareholders will receive newly issued Mast shares in exchange for their Savara stock and own 76% of the combined entity, which will also retain the Savara name and headquarters in Austin, TX. The merger has been approved by both firms’ boards and is subject to Mast and Savara shareholder approval and customary closing conditions.

      Savara is focused on the development of treatments for rare respiratory diseases. If the merger with Mast is finalized, the combined clinical pipeline will include three candidates. Savara’s own AeroVanc is an inhaled dry powder vancomycin for treating methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection in cystic fibrosis. Savara and Mast anticipate starting a Phase III study with AeroVanc during the latter half of 2017. Savara raised $20 million in a Series C financing round, during the first quarter of 2016, to support the Phase III study.

      Mast’s AIR001 is an inhaled, nebulized sodium nitrate solution for treating heart failure with preserved ejection fraction (HFpEF). The drug is in Phase II development. Mast and Savara say they expect to release data from the 100-patient study, which is being conducted by the Heart Failure Clinical Research Network, during the first quarter of 2018.

      Molgradex® is an inhaled, nebulized granulocyte-macrophage colony-stimulating factor (GM-CSF) for treating pulmonary alveolar proteinosis (PAP). The drug is undergoing Phase II/III development. Savara acquired Molgradex through its takeover of Danish firm Serendex Pharmaceuticals in July 2016. Topline data from the registration-enabling European and Japanese trial of Molgradex are expected during the early part of 2018. Molgradex has been available for use in selected PAP patients in Denmark, Germany, and Austria, under the Early Patient Access program, since 2015. During May 2016, Savara granted Japanese firm Nobelpharma a license to Molgradex for the treatment of PAP in Japan.

      Savara’s preclinical candidate Alveodex is a proprietary, nebulized recombinant human FVIIa, which is in development for the treatment of diffuse alveolar hemorrhage and other high-risk populations with respiratory diseases in a critical care setting. Alveodex was also acquired through the Serendex takeover.

      In a statement, Savara chairman and CEO, Rob Neville, called the proposed merger with Mast transformative. “We believe the favorable risk profile of our product candidates combined with their market potential provides a unique opportunity for Savara to become the next breakout company in orphan pulmonary diseases." Brian M. Culley, current CEO and director of San Diego-based Mast Therapeutics, added, "We are excited for the prospects of the combined company and believe that Savara's management team is well equipped to advance the pipeline toward regulatory approvals and commercialization in the U.S. and EU."

    LumiThera Featured at Monaco Growth Forum in UAE

    Monaco Growth Forums celebrates another successful event with the Tech Tour U.A.E.

    The event was attended by over 130 investors in Dubai and Abu Dhabi on December 14th - 15th.

    December 19, 2016 - Monaco Growth Forum's Premier Edition of Tech Tour U.A.E. concluded last Thursday evening after three days of meetings, receptions and luncheons in the Emirates of Dubai and Abu Dhabi. Hosted by Andreea Porcelli and Monica Cressot of Cressot Capital, this unique networking event featured three of the top companies from our Monaco Growth Forums Fall Edition in Monte Carlo held in November.

    Joseph Konowiecki, CEO of Apollo AES shared, “The Tech Tour was both interesting and enlightening. I met a wide variety of companies with which AES may achieve future relationships in the GCC region. I was impressed by the degree with which the UAE could become a springboard for relationships in the global marketplace”

    The CEO's of Apollo AES, ("OAL:GR), Badu Networks, and Lumithera, Inc. met with over 130 investors and business representatives starting on Tuesday in Dubai. this was followed by a Cocktail Reception at the Ritz Carlton in Abu Dhabi on Tuesday evening. Wednesday started with an Investor Luncheon at the Ritz-Carlton in Abu Dhabi and proceeded to a Cocktail Reception at Jean Georges Restaurant at the Four Seasons Resort in Dubai. The Cocktail was attended by over 60 guests including Business Executives, politicians, and other international investors also based in Dubai.

    Clark Tedford, CEO of Lumithera said, “U.A.E. represents an important market for our medical device and has a history of being on the cutting edge of medical technology. The events were an opportunity to meet new collaborators and investors and help us open the doors to bringing our technology here. It was an incredible week for the Tech Tour.”

    “"U.A.E. is a strategic location for BADU beyond just that of a potential market for our products. The U.A.E. is also a strategic location from which BADU can serve its future continental customers from the Middle East, India and Africa,” said Dennis Vadura, CEO of Badu Networks. “We are very happy to have been part of the U.A.E. Tech Tour as it gave us an opportunity to start forging important relationships in the region.”

    Thursday, 15th December was our headline event, the Luncheon presentation at The Address Hotel in Dubai. Over 50 investors watched the company presentations and lingered over a networking lunch well into the late afternoon. Several delegates remarked that they were impressed by the quality of the companies presenting as well as the organization of the Forum.

    Andreea Porcelli, CEO of MGF promised, “We will return to the U.A.E. in February with a Tech Tour as we find the international business and investing environment here to be a real benefit to our high growth company clients. We look forward to meeting you all again and exploring the synergies that we have found here for businesses that are seeking an international representation.”